These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 21686229

  • 21. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt.
    Lea WB, Kwak ES, Luther JM, Fowler SM, Wang Z, Ma J, Fogo AB, Brown NJ.
    Kidney Int; 2009 May; 75(9):936-44. PubMed ID: 19225557
    [Abstract] [Full Text] [Related]

  • 22. Aldosterone receptor antagonists: current perspectives and therapies.
    Guichard JL, Clark D, Calhoun DA, Ahmed MI.
    Vasc Health Risk Manag; 2013 May; 9():321-31. PubMed ID: 23836977
    [Abstract] [Full Text] [Related]

  • 23. Mineralocorticoid antagonism and cardiac hypertrophy.
    Nagata K.
    Curr Hypertens Rep; 2008 Jun; 10(3):216-21. PubMed ID: 18765093
    [Abstract] [Full Text] [Related]

  • 24. The Role of Aldosterone in Obesity-Related Hypertension.
    Kawarazaki W, Fujita T.
    Am J Hypertens; 2016 Apr; 29(4):415-23. PubMed ID: 26927805
    [Abstract] [Full Text] [Related]

  • 25. Aberrant Rac1-mineralocorticoid receptor pathways in salt-sensitive hypertension.
    Kawarazaki W, Fujita T.
    Clin Exp Pharmacol Physiol; 2013 Dec; 40(12):929-36. PubMed ID: 24111570
    [Abstract] [Full Text] [Related]

  • 26. Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.
    Noda K, Kobara M, Hamada J, Yoshifuji Y, Shiraishi T, Tanaka T, Wang J, Toba H, Nakata T.
    J Cardiovasc Pharmacol; 2012 Aug; 60(2):140-9. PubMed ID: 22549451
    [Abstract] [Full Text] [Related]

  • 27. Angiotensin II and aldosterone receptor binding in rat heart and kidney: response to chronic angiotensin II or aldosterone administration.
    Sun Y, Weber KT.
    J Lab Clin Med; 1993 Oct; 122(4):404-11. PubMed ID: 8228554
    [Abstract] [Full Text] [Related]

  • 28. Aldosterone-induced fibrosis in the kidney: questions and controversies.
    Brem AS, Morris DJ, Gong R.
    Am J Kidney Dis; 2011 Sep; 58(3):471-9. PubMed ID: 21705125
    [Abstract] [Full Text] [Related]

  • 29. Effect of aldosterone and MR blockade on the brain and the kidney.
    Stier CT, Rocha R, Chander PN.
    Heart Fail Rev; 2005 Jan; 10(1):53-62. PubMed ID: 15947892
    [Abstract] [Full Text] [Related]

  • 30. Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2).
    Bogman K, Schwab D, Delporte ML, Palermo G, Amrein K, Mohr S, De Vera Mudry MC, Brown MJ, Ferber P.
    Hypertension; 2017 Jan; 69(1):189-196. PubMed ID: 27872236
    [Abstract] [Full Text] [Related]

  • 31. Role of central nervous system aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in Dahl salt-sensitive rats.
    Huang BS, White RA, Jeng AY, Leenen FH.
    Am J Physiol Regul Integr Comp Physiol; 2009 Apr; 296(4):R994-R1000. PubMed ID: 19118098
    [Abstract] [Full Text] [Related]

  • 32. Central and peripheral slow-pressor mechanisms contributing to Angiotensin II-salt hypertension in rats.
    Lu J, Wang HW, Ahmad M, Keshtkar-Jahromi M, Blaustein MP, Hamlyn JM, Leenen FHH.
    Cardiovasc Res; 2018 Feb 01; 114(2):233-246. PubMed ID: 29126194
    [Abstract] [Full Text] [Related]

  • 33. Aldosterone, but not angiotensin II, reduces angiotensin converting enzyme 2 gene expression levels in cultured neonatal rat cardiomyocytes.
    Yamamuro M, Yoshimura M, Nakayama M, Abe K, Sumida H, Sugiyama S, Saito Y, Nakao K, Yasue H, Ogawa H.
    Circ J; 2008 Aug 01; 72(8):1346-50. PubMed ID: 18654024
    [Abstract] [Full Text] [Related]

  • 34. Aldosterone-induced cardiac damage: focus on blood pressure independent effects.
    Schmidt BM, Schmieder RE.
    Am J Hypertens; 2003 Jan 01; 16(1):80-6. PubMed ID: 12517689
    [Abstract] [Full Text] [Related]

  • 35. Involvement of renin-angiotensin-aldosterone system in calcium oxalate crystal induced activation of NADPH oxidase and renal cell injury.
    Tsuji H, Wang W, Sunil J, Shimizu N, Yoshimura K, Uemura H, Peck AB, Khan SR.
    World J Urol; 2016 Jan 01; 34(1):89-95. PubMed ID: 25981400
    [Abstract] [Full Text] [Related]

  • 36. Pharmacological treatment of aldosterone excess.
    Deinum J, Riksen NP, Lenders JW.
    Pharmacol Ther; 2015 Oct 01; 154():120-33. PubMed ID: 26213109
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. A new HOPE for aldosterone blockade?
    Pitt B.
    Circulation; 2004 Sep 28; 110(13):1714-6. PubMed ID: 15451807
    [No Abstract] [Full Text] [Related]

  • 39. Mineralocorticoid receptor activation as an etiological factor in kidney diseases.
    Ueda K, Nagase M.
    Clin Exp Nephrol; 2014 Feb 28; 18(1):16-23. PubMed ID: 23832326
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.